Patents by Inventor Srinivas Cheruku
Srinivas Cheruku has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11713312Abstract: Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.Type: GrantFiled: December 7, 2021Date of Patent: August 1, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Dean A. Wacker, Susheel Jethanand Nara, Srinivas Cheruku, Kandhasamy Sarkunam, Firoz Ali Jaipuri, Soodamani Thangavel, Srinivas Jogi, Pavan Kalyan Kathi
-
Publication number: 20230109670Abstract: Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.Type: ApplicationFiled: February 14, 2020Publication date: April 6, 2023Inventors: Dean A. Wacker, Susheel Jethanand Nara, Srinivas Cheruku, Kandhasamy Sarkunam, Firoz Ali Jaipuri, Rishikesh Narayan, Subba Reddy Bandreddy, Srinivas Jogi
-
Publication number: 20220213026Abstract: Disclosed are compounds of Formula (I) or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is a 5-membered heterocyclyl or 5-membered heteroaryl having 1 to 4 heteroatoms independently selected from N, O, and S, substituted with zero to 4 R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R2, R3a, R3b, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.Type: ApplicationFiled: February 14, 2020Publication date: July 7, 2022Inventors: Dean A. Wacker, Susheel Jethanand Nara, Srinivas Cheruku, Kandhasamy Sarkunam, Firoz Ali Jaipuri, Soodamani Thangavel, Rishikesh Narayan, Subba Reddy Bandreddy, Srinivas Jogi, Pavan Kalyan Kathi
-
Publication number: 20220162201Abstract: Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.Type: ApplicationFiled: February 14, 2020Publication date: May 26, 2022Inventors: Dean A. Wacker, Susheel Jethanand Nara, Srinivas Cheruku, Kandhasamy Sarkunam, Firoz Ali Jaipuri, Rishikesh Narayan, Subba Reddy Bandreddy, Srinivas Jogi
-
Publication number: 20220135550Abstract: Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.Type: ApplicationFiled: December 7, 2021Publication date: May 5, 2022Inventors: Dean A. WACKER, Susheel Jethanand NARA, Srinivas CHERUKU, Kandhasamy SARKUNAM, Firoz Ali JAIPURI, Soodamani THANGAVEL, Srinivas JOGI, Pavan Kalyan KATHI
-
Publication number: 20220081430Abstract: Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, when Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substiuted with zero to 6 R1a, or P(O)R1cR1c, or (ii) L R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R1a, R1c, R2, R3a, R3b, Rx, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.Type: ApplicationFiled: February 14, 2020Publication date: March 17, 2022Inventors: Dean A. Wacker, Susheel Jethanand Nara, Srinivas Cheruku, Kandhasamy Sarkunam, Firoz Ali Jaipuri, Soodamani Thangavel, Rishikesh Narayan, Srinivas Jogi, Pavan Kalyan Kathi
-
Patent number: 11254663Abstract: Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.Type: GrantFiled: February 13, 2020Date of Patent: February 22, 2022Assignee: Bristol-Myers Squibb CompanyInventors: Dean A. Wacker, Susheel Jethanand Nara, Srinivas Cheruku, Kandhasamy Sarkunam, Firoz Ali Jaipuri, Soodamani Thangavel, Srinivas Jogi, Pavan Kalyan Kathi
-
Patent number: 11253525Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.Type: GrantFiled: August 29, 2019Date of Patent: February 22, 2022Assignee: Bristol-Myers Squibb CompanyInventors: James Aaron Balog, Steven P. Seitz, Susheel Jethanand Nara, Saumya Roy, Srinivasan Thangathirupathy, Soodamani Thangavel, Srinivas Cheruku
-
Publication number: 20210355113Abstract: The present invention provides compounds of formula (I) wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.Type: ApplicationFiled: July 20, 2019Publication date: November 18, 2021Inventors: James Aaron BALOG, Steven P. SEITZ, Jay A. MARKWALDER, David K. WILLIAMS, Weifang SHAN, Susheel Jethanand NARA, Saumya ROY, Srinivas CHERUKU, Nagalakshmi PULICHARLA
-
Publication number: 20210299126Abstract: The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.Type: ApplicationFiled: July 22, 2019Publication date: September 30, 2021Inventors: James Aaron BALOG, Jay A. MARKWALDER, Weifang SHAN, David K. WILLIAMS, Susheel Jethanand NARA, Saumya ROY, Soodamani THANGAVEL, Srinivas CHERUKU, Ramesh Kumar SISTLA
-
Publication number: 20210261535Abstract: Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.Type: ApplicationFiled: February 13, 2020Publication date: August 26, 2021Inventors: Dean A. Wacker, Susheel Jethanand Nara, Srinivas Cheruku, Kandhasamy Sarkunam, Firoz Ali Jaipuri, Soodamani Thangavel, Rishikesh Narayan, Subba Reddy Bandreddy, Srinivas Jogi, Pavan Kalyan Kathi
-
Patent number: 10961229Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.Type: GrantFiled: July 3, 2019Date of Patent: March 30, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Imadul Islam, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Srinivas Cheruku, Poornima Shetty, Grandhi Venkat Ram Krishna Mohan Gupta, John E. Macor
-
Patent number: 10963588Abstract: Provided are techniques for analyzing recordings for data to be protected and identifying recipients and alerts. A recording is stored in temporary storage. Data to be protected about a situation is identified in the recording. One or more recipients are identified based on the data to be protected about the situation. One or more alerts for the one or more recipients are identified based on the data to be protected about the situation. The one or more alerts are sent to the one or more recipients along with the recording. The recording is deleted from the temporary storage.Type: GrantFiled: October 30, 2019Date of Patent: March 30, 2021Assignee: International Business Machines CorporationInventors: Srinivas Cheruku, Srinivasulu Reddy Botta, Kasi Gonguntla, Ganesh Devavarapu, Venkata Ratnam Alubelli
-
Patent number: 10954225Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMDA) receptor and thereby making them useful for the treatment of various disorders of the central nervous system.Type: GrantFiled: December 9, 2019Date of Patent: March 23, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Imadul Islam, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Srinivas Cheruku, Poornima Shetty, John E. Macor
-
Patent number: 10730863Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.Type: GrantFiled: October 31, 2018Date of Patent: August 4, 2020Assignee: Bristol-Myers Squibb CompanyInventors: David S. Yoon, Rushith Kumar Anumula, Srinivas Cheruku, Yanting Huang, Elizabeth Anne Jurica, Wei Meng, Susheel Jethanand Nara, Rishikesh Narayan, Ramesh Kumar Sistla, Ximao Wu, Guohua Zhao
-
Publication number: 20200115370Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMDA) receptor and thereby making them useful for the treatment of various disorders of the central nervous system.Type: ApplicationFiled: December 9, 2019Publication date: April 16, 2020Inventors: Imadul Islam, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Srinivas Cheruku, Poornima Shetty, John E. Macor, III
-
Publication number: 20200069695Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.Type: ApplicationFiled: August 29, 2019Publication date: March 5, 2020Inventors: James Aaron Balog, Steven P. Seitz, Susheel Jethanand Nara, Saumya Roy, Srinivasan Thangathirupathy, Soodamani Thangavel, Srinivas Cheruku
-
Publication number: 20200071304Abstract: The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.Type: ApplicationFiled: July 3, 2019Publication date: March 5, 2020Inventors: Imadul Islam, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Srinivas Cheruku, Poornima Shetty, Grandhi Venkat Ram Krishna Mohan Gupta, John E. Macor
-
Patent number: 10501451Abstract: The present disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) compounds are ligands for NR2B N-Methyl-D-aspartate (NMD A) receptor and thereby making them useful for the treatment of various disorders of the central nervous system.Type: GrantFiled: October 13, 2016Date of Patent: December 10, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Imadul Islam, Srinivasan Thangathirupathy, Jayakumar Sankara Warrier, Srinivas Cheruku, Poornima Shetty, John E. Macor
-
Patent number: 10399932Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.Type: GrantFiled: April 1, 2016Date of Patent: September 3, 2019Assignee: Bristol-Myers Squibb CompanyInventors: James Aaron Balog, Emily Charlotte Cherney, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Audris Huang, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla